Privia Health Group, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRVA research report →
Range $24 – $32
Price Chart
About the company
Privia Health Group, Inc. functions as a national entity focused on empowering physicians throughout the United States. It partners with medical groups, health plans, and health systems, with the primary objective of optimizing physician practices, enhancing patient experiences, and appropriately compensating clinicians for care delivered both virtually and in person.
- CEO
- Parth Mehrotra
- IPO
- 2021
- Employees
- 1,226
- HQ
- Arlington, VA, US
Get TickerSpark's AI analysis on PRVA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.20B
- P/E
- 89.78
- Fwd P/E
- 73.04
- PEG
- 0.90
- P/S
- 1.31
- P/B
- 3.92
- EV/EBITDA
- 37.08
- Div Yield
- 0.00%
- Gross Margin
- 10.54%
- Op Margin
- 2.10%
- Net Margin
- 1.43%
- ROE
- 4.50%
- ROIC
- 3.58%
Latest fiscal year · YoY change
- Revenue
- $2.12B+22.3%
- Gross Profit
- $209.43M+18.4%
- Op Income
- $34.23M
- Net Income
- $22.92M+59.3%
- EPS
- $0.19+58.3%
- OCF Growth
- +49.5%
- FCF Growth
- +55.6%
- 52W High
- $28.82
- 52W Low
- $18.91
- 50D MA
- $21.84
- 200D MA
- $22.73
- Beta
- 0.77
- RSI (14)
- 67
- Avg Volume
- 1.33M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Privia Health raised 2026 guidance after a strong first nine months, with provider growth, attribution gains, and disciplined capital deployment all accelerating.· November 5, 2026
- Implemented providers rose 12.2% year over year to 5,893, and attributed lives increased 19.2% in the first nine months of 2026.
- Year-to-date practice collections grew 12% to $2.91 billion, while adjusted EBITDA rose 21.9% to $114.7 million.
- Management lifted 2026 outlook above the high end of initial guidance across key metrics, including adjusted EBITDA growth of 23.9% at the midpoint and 6,000 clinicians by year-end.
- The company ended Q3 with $446.3 million in cash and no debt, and expects at least $520 million in cash at year-end.
- Privia announced a $36 million cash acquisition of American Choice Healthcare MSSP ACO and said the Montana partnership exit should not materially affect 2027 adjusted EBITDA.
Privia reported that first-nine-month practice collections increased 12% year over year to $2.91 billion, and adjusted EBITDA increased 21.9% to $114.7 million, or 28.8% of care margin. Implemented providers increased 12.2% year over year to 5,893, including a sequential increase of 249 from Q2. The company ended the third quarter with $446.3 million in cash and no debt, and expects approximately 70% of full-year adjusted EBITDA to convert to free cash flow. For 2026, management raised guidance above the high end of the initial range: implemented providers are expected to reach the high end of the original guide, attributed lives growth is expected to be 9.2% at the midpoint, practice collections 13.1%, care margin 16.3%, and adjusted EBITDA growth 23.9% at the midpoint. Management also said the American Choice Healthcare acquisition should have minimal impact on 2026 and positive impact in 2027, while the Montana exit is expected to have no material impact on 2027 adjusted EBITDA.
Parth Mehrotra struck an upbeat tone, saying Privia is seeing strong momentum, robust new provider signings, and clear visibility into its implementation pipeline through 2026 and into 2027. He emphasized five growth pillars: organic growth in existing practices, expansion into new care centers and ancillary services, more value-based care attribution, disciplined acquisitions, and adjacent business opportunities. He repeatedly framed the company as opportunistic but disciplined on M&A, with a high bar for transformational deals and a focus on accretive tuck-ins that fit the model.
David Mountcastle highlighted operating leverage and balance sheet strength, pointing to 12.2% implemented provider growth, $2.91 billion in year-to-date practice collections, and $114.7 million of adjusted EBITDA, equal to 28.8% of care margin. He said Privia ended Q3 with $446.3 million in cash and no debt, expects about 70% of full-year adjusted EBITDA to convert to free cash flow, and anticipates at least $520 million in cash at year-end, even after accounting for the American Choice transaction and MSSP settlement timing. He also revised the free cash flow conversion expectation to 70%-75% going forward, citing timing of MSSP payments and the company’s status as a full cash taxpayer with an effective tax rate of about 27%.
Analysts focused on the American Choice acquisition, the Montana exit, the finalized physician fee schedule, MA contracting, and whether growth and margins can keep compounding. Management said American Choice was available at attractive multiples, fits the playbook, and should add attributed lives and adjusted EBITDA in 2027, while Montana was a small, idiosyncratic situation tied to partner priorities and Privia’s high bar for remaining in smaller markets. On the PFS, Parth said the rule was broadly in line with expectations and does not change guidance, and on cash flow David said the 70%-75% conversion target reflects timing and tax realities. Management also reiterated confidence in MA, MSSP, and commercial value-based care, saying the long-term trends remain favorable and the company is well positioned to partner with payers and expand risk-sharing arrangements.
The bullish case is that Privia is still growing quickly while scaling profitability: provider counts, attributed lives, practice collections, and adjusted EBITDA all improved meaningfully, and management raised full-year guidance above prior targets. The company has a large cash balance, no debt, and repeatedly emphasized capacity to do more accretive deals or potentially return capital if attractive M&A is not available.
The main risks raised were integration and execution on acquisitions, the ongoing complexity of value-based care programs, and changing payer/regulatory dynamics such as MA benefit design, star scores, and attribution shifts. Management also acknowledged that some businesses and markets are not a fit at current scale, as shown by the Montana exit, and that free cash flow conversion can vary with MSSP settlement timing and tax payments.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 85.0%
- Shares Outstanding
- 127.77M
- Float Shares
- 108.65M
of shares held by institutions
306 13F filers
Buy/sell ratio 0.40. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 22.65M | ▲ 1.25M |
| Vanguard Group Inc | 12.00M | ▼ 102.96K |
| Durable Capital Partners LP | 11.97M | ▲ 335.02K |
| Fmr LLC | 6.83M | ▼ 6.02M |
| Vanguard Portfolio Management LLC | 6.79M | ▲ 221.86K |
| Rubicon Founders LLC | 6.47M | ▲ 501.43K |
| Vanguard Capital Management LLC | 5.54M | ▲ 385.95K |
| State Street Corp | 5.15M | ▲ 239.30K |
| Van Berkom & Associates Inc. | 3.69M | ▼ 26.21K |
| Wellington Management Group Llp | 3.52M | ▲ 1.39M |
| Geode Capital Management, LLC | 3.20M | ▲ 72.62K |
| Riverbridge Partners LLC | 2.90M | ▼ 103.31K |
Held by 404 ETFs
Biggest fund positions in PRVA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 1, 26 | Ernest Opella Finley | other | 6,350 |
| Sep 1, 26 | Ernest Opella Finley | other | 0 |
| Jul 9, 26 | Mountcastle David | sell | 21,275 |
| Jul 7, 26 | Mountcastle David | sell | 600 |
| Jul 2, 26 | Morris Matthew Shawn | other | 59,037 |
| Jul 6, 26 | Morris Matthew Shawn | other | 53,722 |
| Jul 2, 26 | Morris Matthew Shawn | other | 59,037 |
| Jul 6, 26 | Morris Matthew Shawn | other | 53,722 |
| Jul 2, 26 | Morris Matthew Shawn | sell | 59,037 |
| Jul 6, 26 | Morris Matthew Shawn | sell | 53,722 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PRVA coverage
Recent articles, reports, and earnings notes.
Want a deeper read on PRVA?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Can Privia Health (PRVA) Run Higher on Rising Earnings Estimates?
zacks.com · Nov 19
Privia Health Reports Strong Results in the 2025 Performance Year of the Medicare Shared Savings Program
globenewswire.com · Nov 18
3 Reasons Why Growth Investors Shouldn't Overlook Privia Health (PRVA)
zacks.com · Nov 10
How Much Upside is Left in Privia Health (PRVA)? Wall Street Analysts Think 29.22%
zacks.com · Nov 10
CenterBook Partners LP Acquires New Shares in Privia Health Group, Inc. $PRVA
defenseworld.net · Nov 10
Privia Health Group Q3 Earnings Call Highlights
marketbeat.com · Nov 6
Privia Health Group, Inc. (PRVA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
Privia Health (PRVA) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
zacks.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
